Pharmacologic targeting of DDR2 with an allosteric inhibitor such as CR13452, which acts via the extracellular region, blocks all DDR2-dependent cellular effects, including tyrosine kinase-independent effects, in tumor cells and CAFs. The gene discussed is DDR2; the disease is neoplasm.